{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00026206", "CSN": null, "TRF": "ORD_1544965_01", "MRN": "21930687", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1263261", "clinicalId": "1264630", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1544965_01", "SampleName": "US1477649.01", "Version": "0", "Sample": {"FM_Id": "ORD_1544965_01", "SampleId": "US1477649.01", "BlockId": "S111-54715A", "TRFNumber": "ORD_1544965_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2023_01_16", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "35", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10027", "MRN": "21930687", "FullName": "\u6797\u5fb7\u8ce2", "FirstName": "Te Hsien", "LastName": "Lin", "SubmittedDiagnosis": "Brain anaplastic astrocytoma", "Gender": "Male", "DOB": "1954_08_12", "OrderingMD": "\u8a31\u79c9\u6b0a", "OrderingMDId": "109266", "Pathologist": "\u6797\u58eb\u5091", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Brain", "CollDate": "2022_12_27", "ReceivedDate": "2023-02-06 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Diffuse Glioma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "17", "clinicalTrialCount": "17", "resistiveCount": "0", "sensitizingCount": "3"}, "VariantProperties": {"VariantProperty": [{"geneName": "ALK", "isVUS": "true", "variantName": "V163L"}, {"geneName": "DOT1L", "isVUS": "true", "variantName": "A1266T"}, {"geneName": "GATA6", "isVUS": "true", "variantName": "A179_A183del"}, {"geneName": "INPP4B", "isVUS": "true", "variantName": "I342V"}, {"geneName": "MET", "isVUS": "true", "variantName": "S1040P"}, {"geneName": "MLL2", "isVUS": "true", "variantName": "S3781N"}, {"geneName": "NOTCH1", "isVUS": "true", "variantName": "E1563D"}, {"geneName": "NOTCH3", "isVUS": "true", "variantName": "A102T"}, {"geneName": "PDCD1LG2 (PD_L2)", "isVUS": "true", "variantName": "P228S"}, {"geneName": "TET2", "isVUS": "true", "variantName": "H658Y"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "EGFR", "Include": "true", "Alterations": {"Alteration": {"Name": "A289V", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "25", "isEquivocal": "false", "name": "A289V"}}, "Interpretation": "EGFR encodes the epidermal growth factor receptor, which belongs to a class of proteins called receptor tyrosine kinases. In response to signals from the environment, EGFR passes biochemical messages to the cell that stimulate it to grow and divide (Ciardiello and Tortora, 2008; 18337605). The EGFR A289V mutation, located in the extracellular domain, has been shown to be activating (Lee et al., 2006; 17177598). Glioblastoma cell lines harboring an EGFR A289V or A289D mutation were shown to be dependent on EGFR kinase activity (Vivanco et al., 2012; 22588883), and other mutations at this position are also likely activating. In addition, A289V is frequently associated with increased EGFR gene copy number (Lee et al., 2006; 17177598). EGFR alterations have been reported in 13.2% of anaplastic astrocytomas, 5.3_15.9% of glioblastoma multiformes (GBMs), and 0% of pilocytic astrocytomas in several genomic studies of CNS tumors (cbio_Jonsson et al., 2019; 31263031, cbio_Brennan et al., 2013; 24120142, cbio_Ceccarelli et al., 2016; 26824661, cbio_Thomas et al., 2017; 28472509). In GBMs, Missense mutations in the EGFR extracellular domain have been found in 10_15% of cases and approximately half have a low_level amplification of the mutated allele (Lee et al., 2006; 17177598, Vivanco et al., 2012; 22588883). EGFR amplification and/or EGFR expression in glioma has been correlated with poor overall survival in patients under 60 years of age, prolonged survival in patients over the age of 60, and tumor grade (Smith et al., 2001; 11504770, Shinojima et al., 2003; 14583498, Ambroise et al., 2010; 21133628, Hobbs et al., 2012; 22472960). For patients with non_small cell lung cancer (NSCLC), EGFR activating mutations may predict sensitivity to EGFR\u2013TKIs, including erlotinib (Rosell et al., 2011; 22285168), gefitinib (Douillard et al., 2014; 24263064, Hayashi et al., 2020; 32673682, Cao et al., 2018; 29780256, Yang et al., 2011; 21422421), afatinib (Sequist et al., 2013; 23816960, Bao_Dong Qin et al., 2018; 30127622, Frega et al., 2016; 27131295, Long et al., 2020; 33116645), dacomitinib (Mok et al., 2018; 29864379), and osimertinib (Janne et al., 2015; 25923549, Bao_Dong Qin et al., 2018; 30127622); however, the data for patients with other tumor types are limited (Hong et al., 2020; 32749686, Kim et al., 2015; 26462025, Kim et al., 2015; 25424851, Mondal et al., 2020; 32303840, Cavalieri et al., 2018; 29734047, Chi et al., 2020; 32923886, Audet et al., 2013; ASCO Abstract 6041). Patients with EGFR_mutated bithalamic glioma have reported responses to osimertinib (Makhlin et al., 2019; 31769726, Goyal et al., 2021; 33940677, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). In a case series of 11 patients with bithalamic gliomas with EGFR mutations, EGFR inhibitors, including osimertinib, showed improved survival; however, it showed a lack of significant clinical responses (Mondal et al., 2020; 32303840). On the basis of preclinical data, EGFR mutations confer sensitivity to EGFR inhibitors, including osimertinib (Mondal et al., 2020; 32303840).", "Include": "true", "ClinicalTrialNote": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Gefitinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Gefitinib targets the tyrosine kinase EGFR and is FDA approved to treat non_small cell lung cancer (NSCLC) harboring exon 19 deletions or exon 21 (L858R) substitution mutations in EGFR. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Activation of EGFR may predict sensitivity to therapies such as gefitinib. Clinical studies have consistently shown significant improvement in response rates and PFS for patients with EGFR_mutated non_small cell lung cancer (NSCLC) treated with gefitinib compared with chemotherapy (Han et al., 2012; 22370314, Maemondo et al., 2010; 20573926, Mitsudomi et al., 2010; 20022809, Mok et al., 2009; 19692680, Petrelli et al., 2011; 22056888, Qi et al., 2015; 25329826, Zhao et al., 2015; 25546556), and responses have been reported for patients with EGFR_rearranged NSCLC (Wang et al., 2018; 30255937, Baik et al., 2015; 26398831). </p> <p><b>Supporting Data:</b> A clinical study of patients with glioblastoma (GBM) treated with gefitinib or erlotinib found that 9/49 (18%) had tumor shrinkage of 25% or more; in this study, the extracellular domain EGFRvIII mutation was correlated with response (Mellinghoff et al., 2005; 16282176). A Phase 2 clinical study of gefitinib in patients with high_grade glioma (including GBM, anaplastic astrocytoma, and oligodendroglioma) reported 18% (5/28) disease stabilization; efficacy was not correlated with EGFR expression (Franceschi et al., 2007; 17353924). However, a Phase 1/2 clinical trial of gefitinib combined with radiotherapy in 178 patients with GBM reported no overall survival benefit of added gefitinib, and EGFR expression was found to be of no prognostic value for patients treated with gefitinib plus radiotherapy (Chakravarti et al., 2013; 23182702). A Phase 2 trial of preoperative gefitinib treatment in patients with recurrent GBM reported that although EGFR phosphorylation was decreased in treated patients as compared to the control group, measurement of 12 downstream molecules revealed no significant changes (Hegi et al., 2011; 21471286). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Osimertinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Osimertinib is an irreversible EGFR TKI that is selective for EGFR TKI_sensitizing mutations and the EGFR T790M mutation. It is FDA approved in various treatment settings for patients with non_small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions, exon 21 L858R mutations, or T790M mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> EGFR TKI_sensitizing mutations or rearrangements and/or the EGFR T790M mutation may predict sensitivity to osimertinib in non_small cell lung cancer (Janne et al., 2015; 25923549, Soria et al., 2018; 29151359, Alanazi et al., 2020; 33318755, Kim et al., 2021; DOI: 10.1200/PO.20.00296, Wang et al., 2018; 30255937). EGFR mutations may confer sensitivity to osimertinib on the basis of clinical responses to the third_generation TKI osimertinib for patients with EGFR_mutated glioma (Makhlin et al., 2019; 31769726, Goyal et al., 2021; 33940677) and additional clinical studies suggesting clinical benefit for these patients (Mondal et al., 2020; 32303840, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). </p> <p><b>Supporting Data:</b> Clinical benefit from osimertinib has been observed for cases of pediatric and adult patients with EGFR_altered glioma (Makhlin et al., 2019; 31769726, Goyal et al., 2021; 33940677, Cardona et al., 2021; 34498213, Mondal et al., 2020; 32303840, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). Osimertinib has been studied primarily for the treatment of EGFR_mutated NSCLC. The Phase 3 FLAURA study reported that, relative to erlotinib or gefitinib, first_line osimertinib significantly increased both median PFS (mPFS; 18.9 vs. 10.2 months, HR=0.46) and median OS (38.6 vs. 31.8 months; HR=0.80) for patients with advanced non_small cell lung cancer (NSCLC) and activating, sensitizing EGFR mutations (specifically, exon 19 deletion or L858) (Soria et al., 2018; 29151359, Ramalingam et al., 2019; 31751012). In the Phase 3 ADAURA study, patients with early_stage (IB/II/IIIA) EGFR_mutated NSCLC experienced longer disease_free survival on osimertinib compared with placebo in the adjuvant setting (65.8 vs. 28.1 months, HR=0.27) (Tsuboi et al., 2022; ESMO Abstract LBA47). A Phase 1 study reported that T790M_negative patients with acquired EGFR TKI resistance experienced an ORR of 21% and a median PFS of 2.8 months (Janne et al., 2015; 25923549). A Phase 1b/2 study evaluating osimertinib in combination with the CD73 inhibitor oleclumab for patients with advanced EGFR_mutated, T790M_negative NSCLC reported an ORR of 19% (4/21), a DCR of 81%, and mPFS of 11 months (Kim et al., 2021 AACR Abstract CT163). A Phase 2 study of osimertinib for EGFR_TKI_naive patients with metastatic or recurrent NSCLC and uncommon EGFR mutations reported a 50% (18/36) ORR and an 89% (32/36) DCR with a median PFS of 8.2 months and a median duration of response of 11.2 months; patients harboring L861Q, G719X, or S768I mutations had ORRs of 78% (7/9), 53% (10/19), and 38% (3/8), respectively (Cho et al., 2020; 31825714). A Phase 2 trial of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with untreated advanced non_small cell lung cancer (NSCLC) harboring EGFR del19 or L858R reported no difference in ORR (82% vs 86%) and median PFS (22.1 vs 20.2 months, HR 0.862 p=0.213) (Kenmotsu et al., 2022; 35636696). The Phase 2 BOOSTER study of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with advanced NSCLC with EGFR_sensitizing mutations (exon 19 del or L858R) and L790M at progression on prior EGFR TKI reported no difference in ORR (55% vs 55%), median OS (24.0 vs 24.3 months, HR 1.03 p=0.91), or median PFS (15.4 vs 12.3 months, HR 0.96 p=0.83), although improved PFS was observed for the combination in the subgroup of current or former smokers (16.5 vs 8.4, HR 0.52) while nonsmokers had no benefit (HR 1.47) (Soo et al., 2021; ESMO Abstract VP3_2021). The Phase 1b TATTON study of osimertinib in combination with selumetinib, savolitinib, or durvalumab for patients with previously treated EGFR_mutated NSCLC reported ORRs of 42% (15/36), 44% (8/18), and 44% (10/23), respectively (Oxnard et al., 2020; 32139298). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Erlotinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Erlotinib is a small_molecule inhibitor of EGFR. It is FDA approved as a monotherapy or in combination with ramucirumab for patients with metastatic non_small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) mutations. Erlotinib is also FDA approved in combination with gemcitabine as a first_line treatment for advanced pancreatic cancer. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Amplification or activation of EGFR may predict sensitivity to therapies such as erlotinib. For patients with activating mutations in EGFR, treatment with erlotinib has been associated with improved response and lengthened time to progression (Cappuzzo et al., 2010; 20493771, Rosell et al., 2012; 22285168, Zhong et al., 2019; 31194613, Petrelli et al., 2011; 22056888). </p> <p><b>Supporting Data:</b> In the MyPathway Phase 2a basket study for advanced solid tumors, 1 of 9 patients with EGFR activation mutations responded to erlotinib monotherapy; the responding patient had urethral adenocarcinoma (Hainsworth et al., 2018; 29320312). A patient with EGFR_mutated metastatic lacrimal gland adenoid cystic carcinoma experienced clinical benefit from erlotinib treatment that was ongoing at 14 months (Nie et al., 2018; 29998897). A clinical study of patients with glioblastoma (GBM) treated with gefitinib or erlotinib found that 9/49 (18%) had tumor shrinkage of 25% or more; in this study, the extracellular domain EGFRvIII mutation was correlated with response (Mellinghoff et al., 2005; 16282176). In a Phase 2 study of 65 patients with GBM or gliosarcoma, treatment with erlotinib, temozolomide, and radiotherapy resulted in longer progression_free survival relative to a historical control study utilizing a regimen of temozolomide and radiotherapy alone (19.3 months vs. 14.1 months)(Prados et al., 2009; 19075262). However, in a Phase 1/2 trial of erlotinib monotherapy in 11 patients with relapsed or refractory GBM or anaplastic astrocytoma, all patients showed disease progression and the drug showed significant toxicity (Kesavabhotla et al., 2012; 22946346). In addition, a Phase 2 trial of patients with recurrent or progressive GBM treated with erlotinib and sorafenib did not meet its objective of a 30% increase in overall survival time compared with historical controls; sorafenib was found to increase erlotinib clearance (Peereboom et al., 2013; 23328813). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT03783403", "Include": "true"}, {"nctId": "NCT04946968", "Include": "true"}, {"nctId": "NCT04616196", "Include": "true"}, {"nctId": "NCT04720976", "Include": "true"}, {"nctId": "NCT02800486", "Include": "true"}, {"nctId": "NCT04670679", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "PTEN", "Include": "true", "Alterations": {"Alteration": {"Name": "E314fs*3", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "41.79", "isEquivocal": "false", "name": "E314fs*3"}}, "Interpretation": "PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K_AKT_mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis (Simpson and Parsons, 2001; 11237521). Alterations such as seen here may disrupt PTEN function or expression (Campbell et al., 2003; 12857747, Rodr\u00edguez_Escudero et al., 2011; 21828076, He et al., 2013; 23475934, Han et al., 2000; 10866302, Myers et al., 1998; 9811831, Pradella et al., 2014; 24498881, Kim et al., 2011; 21536651, Denning et al., 2007; 17213812, Hlobilkova et al., 2006; 16619501, Redfern et al., 2010; 20718038, Shenoy et al., 2012; 22505997, Wang et al., 2009; 19329485, Okumura et al., 2006; 16829519, Lee et al., 1999; 10555148, Maxwell et al., 1998; 9635567, Risinger et al., 1998; 9865913, Kato et al., 2000; 11051241, Fenton et al, 2012; 22891331, Ngeow et al., 2012; 23066114, Lobo et al., 2009; 19457929, Liu et al., 2014; 23995781, Maehama et al., 2001; 11395408, De Vivo et al., 2000; 10807691, Ramaswamy et al., 1999; 10051603, Liu et al., 2005; 15988030, Karoui et al., 2004; 15026806, Gil et al., 2015; 25875300, Furnari et al., 1998; 9823298, Spinelli et al., 2015; 25527629, Mingo et al., 2018; 29706633, Wang et al., 2010; 20538496, Andr\u00e9s_Pons et al., 2007; 17942903, Butler et al., 2005; 15805158, Lee et al., 1999; 10555148, Georgescu et al., 1999; 10468583, Staal et al., 2002; 12085208, Nguyen et al., 2013; 24292679, Rahdar et al., 2009; 19114656, Das et al., 2003; 12808147, Wang et al., 2008; 18498243, Valiente et al., 2005; 15951562, Nguyen et al., 2015; 25263454, Shan et al., 2020; 32704382). Studies in the literature have indicated that PTEN alterations (mutation or homozygous deletion) occur most frequently in glioblastoma (GBM), less frequently in anaplastic astrocytoma, and rarely in lower grade glioma subtypes including low grade astrocytoma, oligodendroglioma, oligoastrocytoma, and ependymoma (Zhou et al., 1999; 10096247, Rasheed et al., 1997; 9331072, Davies et al., 1999; 10188904, Smith et al., 2001; 11504770, Lin et al., 1998; 9796977, Schmidt et al., 1999; 10560660, Kato et al., 2000; 11051241, Furnari et al., 2007; 17974913). One study detected PTEN mutation in 42% (97/232) and loss in 10% (24/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). In the TCGA dataset, PTEN mutation was observed in 23% of GBM cases and PTEN deletion was reported in 7% of cases (cBio_Brennan et al., 2013; 24120142), while in the Lower Grade Glioma TCGA dataset, PTEN mutation was observed in 4% of cases and homozygous deletion observed in 1.2% of cases (Cancer Genome Atlas Research Network., 2015; 26061751). Loss of PTEN correlated with significantly worse prognosis in all grades of gliomas (Lin et al., 1998; 9796977, Srividya et al., 2011; 21134002). PTEN loss or mutation leads to activation of the PI3K_AKT_mTOR pathway and may predict sensitivity to inhibitors of this pathway (Courtney et al., 2010; 20085938, Simpson and Parsons, 2001; 11237521, Patnaik et al., 2016; 27672108, Milella et al., 2017; 28220839). Across various tissues, most clinical studies have not observed an association between PTEN deficiency and response to inhibitors of the PI3K_AKT_mTOR pathway. However, limited studies in prostate cancer (Templeton et al., 2013; 23582881, Sweeney et al., 2021; 34246347, de Bono et al., 2019; 30037818, Saura et al., 2017; 27872130), renal cell carcinoma (Voss et al., 2019; 30327302), breast cancer (Andre et al., 2016; 27091708, Dent et al., 2018; ASCO Abstract 1008, Schmid et al., 2020; 31841354), and colorectal cancer (Gilcrease et al., 2019; 30302599) have reported an association between PTEN deficiency and response to inhibitors targeting the PI3K_AKT_mTOR pathway. Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors (Mendes_Pereira et al., 2009; 20049735, Shen et al., 2013; 23881923, Chatterjee et al., 2013; 23565244, McCormick et al., 2016; 26905328, Forster et al., 2011; 21468130), and clinical benefit has been observed for patients with PTEN_altered breast cancer including triple negative breast cancer (Gruber et al., 2019; ASCO Abstract 3006, Eikesdal et al., 2021; 33242536), ovarian cancer (Dougherty et al., 2014; ASCO Abstract 5536), uterine leiomyosarcoma (Pan et al., 2021; 33970096), and endometrial cancer (Forster et al., 2011; 21468130) treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity (Sandhu et al., 2013; 23810788, Romero et al., 2020; 32988624, Piha_Paul et al., 2018; AACR Abstract A096). PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte_Duclos disease (LD), Bannayan_Riley_Ruvalcaba syndrome (BRRS), PTEN_related Proteus syndrome (PS), and Proteus_like syndrome (Blumenthal and Dennis, 2008; 18781191, Orloff and Eng, 2008; 18794875). The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients (Blumenthal and Dennis, 2008; 18781191, Zbuk and Eng, 2007; 17167516). The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder (Blumenthal and Dennis, 2008; 18781191). Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.", "Include": "true", "ClinicalTrialNote": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04740190", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT05035745", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT05076513", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04317105", "Include": "true"}, {"nctId": "NCT05297864", "Include": "true"}, {"nctId": "NCT02484404", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "ERRFI1", "Include": "true", "Alterations": {"Alteration": {"Name": "loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "loss"}}, "Interpretation": "The ERRFI1 gene (also known as MIG6 or RALT) encodes a tumor suppressor that negatively regulates the ERBB family of receptors (Anastasi et al., 2003; 12833145, Anastasi et al., 2007; 17599051, Zhang et al., 2007; 18046415, Anastasi et al., 2005; 15856022), and is transcriptionally activated by RAS_RAF_ERK signaling (Fiorini et al., 2002; 12226756). ERRFI1 directly binds to the kinase domain of ERBB proteins and consequently antagonizes their oncogenic signaling and cell proliferation (Anastasi et al., 2003; 12833145, Anastasi et al., 2007; 17599051, Zhang et al., 2007; 18046415, Anastasi et al., 2005; 15856022). ERRFI1 also negatively regulates signaling by promoting EGFR endocytosis and degradation (Frosi et al., 2010; 20421427, Ying et al., 2010; 20351267). Knockout or depletion of ERRFI1 was shown to result in EGFR and ERBB2/ERBB3 activation (Fiorini et al., 2002; 12226756, Ferby et al., 2006; 16648858, Reschke et al., 2010; 20044804, Ying et al., 2010; 20351267), and disruption of the ERRFI1 gene promoted tumorigenesis in mice (Ferby et al., 2006; 16648858, Zhang et al., 2007; 16819504), whereas overexpression of ERRFI1 inhibited EGFR_ or ERBB2_mediated signaling and oncogenic transformation in vitro (Hackel et al., 2001; 11843178, Fiorentino et al., 2000; 11003669, Ying et al., 2010; 20351267). Alterations such as seen here may disrupt ERRFI1 function or expression (Zhang et al., 2007; 18046415, Anastasi et al., 2003; 12833145). ERRFI1 mutations have been reported in 0_1% of low_grade glioma and glioblastoma samples across several genomic studies (cBio_Brennan et al., 2013; 24120142, Ceccarelli et al., 2016; 26824661, Zehir et al., 2017; 28481359). Published data investigating the prognostic implications of ERRFI1 alterations in glioma are limited (PubMed, Nov 2022). ERRFI1 loss or inactivating mutations may result in EGFR activation and predict sensitivity to ERBB tyrosine kinase inhibitors such as erlotinib, gefitinib, afatinib, and lapatinib, which are approved to treat lung or breast cancers. One patient with cholangiocarcinoma and an ERRFI1 loss of function mutation was reported to have a partial response to the EGFR inhibitor erlotinib (Borad et al., 2014; 24550739). In preclinical studies, the EGFR inhibitor gefitinib was reported to cause regression of tumors in ERRFI1 knockout mice (Ferby et al., 2006; 16648858) and inhibit signaling downstream EGFR in ERRFI1_depleted human cell lines (Walsh and Lazarra., 2013; 23868981).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_High has been reported in 3_8% of adult or pediatric astrocytomas and was generally not associated with Lynch syndrome (Alonso et al., 2001; 11280776, Rodr\u00edguez_Hern\u00e1ndez et al., 2013; 24073290, Vladimirova et al., 2008; 18053027). Low_level MSI has been reported in 5_9% of glioblastoma (GBM) samples (Martinez et al., 2004; 15331927, Martinez et al., 2005; 15672285, Martinez et al., 2007; 17498554). A large_scale study did not find high_level microsatellite instability (MSI_H) in any of 129 GBM samples (Martinez et al., 2004; 15331927), although a small_scale study reported MSI_H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs (Szybka et al., 2003; 12908754). The frequency of MSI has been reported to be increased in relapsed compared to primary GBM (Martinez et al., 2004; 15331927), in GBMs with a previous lower grade astrocytoma (Martinez et al., 2005; 15672285), and in giant cell GBM compared to classic GBM (Martinez et al., 2007; 17498554). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "RB1", "Include": "true", "Alterations": {"Alteration": {"Name": "loss exons 18_27", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "loss exons 18_27"}}, "Interpretation": "RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle (Burkhart and Sage, 2008; 18650841, Knudsen and Knudsen, 2008; 19143056). Alterations such as seen here may disrupt RB1 function or expression (Berge et al., 2010; 20594292, Giacinti et al., 2006; 16936740, Otterson et al., 1997; 9342358, Otterson et al., 1999; 10486322, Qin et al., 1992; 1534305, Rubin et al., 2005; 16360038, Sun et al., 2006; 16449662). In low_grade gliomas, alteration in the Rb pathway, including homozygous deletion and promoter methylation of CDKN2A, CDKN2B, and RB1, is reported to occur in 26% of cases lacking IDH1/2, TP53, or 1p/19q alterations, and in 11% of tumors harboring these alterations (Kim et al., 2011; 21470325). Loss of heterozygosity at the RB1 locus has been reported in 28_30% of high_grade astrocytomas, and specifically in 19% of anaplastic astrocytoma cases in one study (Ichimura et al., 1996; 8806696, Henson et al., 1994; 7979217, Gonzalez_Gomez et al., 2003; 12556968). Promoter hypermethylation of RB1 has also been observed in 6_19% of malignant astrocytomas, with one study citing RB1 promoter methylation in 14% of anaplastic astrocytomas (Ohta et al., 2006; 17016577, Gonzalez_Gomez et al., 2003; 12556968). In the TCGA datasets, RB1 mutation or homozygous deletion was observed in 9% of glioblastomas (cBio_Brennan et al., 2013; 24120142) and 2.5% of lower grade glioma cases (Cancer Genome Atlas Research Network., 2015; 26061751). In patients with low_grade diffuse gliomas, Rb pathway alterations have been significantly associated with poor clinical outcome (Kim et al., 2011; 21470325, B\u00e4cklund et al., 2005; 15970925). On the basis of limited clinical data (Owonikoko et al., 2016; ESMO Abstract 14230) and strong preclinical data (Hook et al., 2012; 22222631, Gong et al., 2019; 30373917, Oser et al., 2019; 30373918, Yang et al., 2022; 34741392), RB1 inactivation may be associated with sensitivity to inhibitors of Aurora kinase A, particularly in small cell lung cancer (SCLC). A clinical study evaluating the Aurora kinase A inhibitor alisertib for patients with prostate cancer did not find an association between RB1 deletion and clinical benefit (Beltran et al., 2019; 30232224). Other approaches to target RB1 inactivation under investigation in preclinical studies include inhibitors of BCL_2 family members (Allaman_Pillet et al., 2013; 21955141) and activation of the NOTCH pathway (Viatour et al., 2011; 21875955). Mutations in RB1 underlie the development of retinoblastoma (RB), a rare tumor that arises at a rate of approximately 1:20,000 live births, with nearly 5,000 new cases worldwide per year (Chen et al., 2014; 24282159). Germline mutations in RB1 account for approximately 40% of RB tumors (Yun et al., 2011; 22553621) and are associated with an increased risk of developing secondary malignancies that include soft tissue and bone sarcoma and malignant melanoma (Houston et al., 2011; 21139478, Ng et al., 2010; 19959033). In the appropriate clinical context, germline testing of RB1 is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TERT", "Include": "true", "Alterations": {"Alteration": {"Name": "promoter _124C>T", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "36.88", "isEquivocal": "false", "name": "promoter _124C>T"}}, "Interpretation": "Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length (Shay et al., 2011; 22015685). Activation of TERT is a hallmark of cancer, being detected in up to 80_90% of malignancies and absent in quiescent cells (Shay et al., 1997; 9282118, Kim et al., 1994; 7605428, Hanahan and Weinberg, 2000; 10647931). Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at _124 bp and _146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)(Horn et al., 2013; 23348503, Huang et al., 2014; 23348506, Vinagre et al., 2013; 23887589), as well as tandem mutations at positions \u2013124/\u2013125 bp and \u2013138/\u2013139 bp (Horn et al., 2013; 23348503). TERT promoter mutations have been reported in 51_59% of gliomas (Killela et al., 2013; 23530248, Killela et al., 2014; 24722048), most frequently in glioblastoma (GBM, 54_84%), gliosarcoma (81%), oligodendroglioma (78%), and historically in oligoastrocytomas (25_31%) but less frequently in lower grade astrocytomas (10_18%) and in only 1% of ependymomas (Nonoguchi et al., 2013; 23955565, Liu et al., 2013; 23603989, Koelsche et al., 2013; 24154961, Killela et al., 2013; 23530248, Killela et al., 2014; 24722048). TERT promoter mutation has been shown to be significantly associated with increased TERT gene expression in astrocytoma, oligodendroglioma, and GBM (Arita et al., 2013; 23764841). TERT promoter mutations significantly associate with poor prognosis in patients with GBM, although this correlation may be due to the association with primary GBM as opposed to IDH_positive secondary GBM (Killela et al., 2013; 23530248, Nonoguchi et al., 2013; 23955565, Reitman et al., 2013; 24217890, Arita et al., 2013; 23764841). In the context of IDH_wildtype glioma, TERT mutations are associated with reduced OS (NCCN CNS Cancers Guidelines, v1.2022). Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches have been investigated, including immunotherapies using TERT as a tumor_associated antigen and antisense oligonucleotide_ or peptide_based therapies. TERT peptide vaccines showed limited anticancer efficacy in clinical trials (Zanetti et al., 2017; 27245281); however, in one preclinical study, the combination of a TERT peptide vaccine and anti_CTLA_4 therapy suppressed tumor growth (Duperret at al., 2018; 29249395). A Phase 2 study of the TERT inhibitor imetelstat for patients with advanced non_small cell lung cancer reported no improvement in PFS or OS (Chiappori et al., 2015; 25467017). TERT mutations are associated with 1p/19q co_deletion in oligodendrogliomas, and are highly recurrent in IDH/ATRX_wildtype glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v1.2022)(Weller et al., 2020; 33293629). The presence of EGFR gene amplification or TERT promoter mutations are indicative of diffuse astrocytic glioma with molecular features of glioblastoma, WHO grade 4 in IDH1/2_wildtype tumors (NCCN CNS Cancers Guidelines, v1.2022) (Louis et al., 2021; 34185076).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "04", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "04"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Touat et al., 2020; 32322066, Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556, Lukas et al., 2018; 30073642). Anaplastic astrocytoma harbors a median TMB of 1.8 mutations per megabase (muts/Mb), and 2% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). For pediatric patients, high TMB has been reported in a subset of high_grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB (Patel et al., 2020; 32386112, Johnson et al., 2017; 28912153). Increased TMB has been reported to correlate with higher tumor grade in glioma (Draaisma et al., 2015; 26699864) and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD) (Bouffet et al., 2016; 27001570), as well as with shorter OS of patients with diffuse glioma (Wang et al., 2020; 32164609). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported (Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Touat et al., 2020; 32322066). However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti_PD_1 (Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556) or anti_PD_L1 (Lukas et al., 2018; 30073642) therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD_1 or PD_L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "EGFR", "Alteration": "A289V", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "A289V", "Title": "A Study of CC_95251, a Monoclonal Antibody Directed Against SIRP\u03b1, in Subjects With Advanced Solid and Hematologic Cancers", "StudyPhase": "PHASE 1", "Target": "CD20, EGFR, SIRP_alpha", "Locations": "Seoul (Korea, Republic of), Heidelberg (Australia), Melbourne (Australia), Manchester (United Kingdom), Edmonton (Canada), Rouen (France), Oregon, Marseille (France), Creteil (France), Nantes Cedex 01 (France)", "NCTID": "NCT03783403", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "A289V", "Title": "Phase_2 Dacomitinib Study on Patients With EGFR_Driven Advanced Solid Tumours With Low EGFR_AS1 IncRNA Expr or Other Novel Emerging Biomarkers", "StudyPhase": "PHASE 2", "Target": "ERBB4, EGFR, ERBB2", "Locations": "Singapore (Singapore)", "NCTID": "NCT04946968", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "A289V", "Title": "Study of NKTR 255 in Combination With Cetuximab in Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "EGFR", "Locations": "California, Montana, Arizona, Minnesota, Illinois, Michigan, Texas, New York", "NCTID": "NCT04616196", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "A289V", "Title": "JAB_3312 Activity in Adult Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "MEK, SHP2, PD_1, EGFR, KRAS", "Locations": "Utah, California, Arizona, Minnesota, Illinois, Michigan, Oklahoma, Missouri, Indiana, Connecticut", "NCTID": "NCT04720976", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "A289V", "Title": "Super Selective Intra_arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA", "StudyPhase": "PHASE 2", "Target": "EGFR", "Locations": "New York", "NCTID": "NCT02800486", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "A289V", "Title": "A Dose Escalation/Expansion Study of ERAS_601 in Patients With Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1", "Target": "SHP2, EGFR", "Locations": "Perth (Australia), Melbourne (Australia), Nevada, California, Texas, Massachusetts, New York, Tennessee, Florida", "NCTID": "NCT04670679", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "E314fs*3", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "E314fs*3", "Title": "Talazoparib _ Carboplatin for Recurrent High_grade Glioma With DDRd", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Hong Kong (Hong Kong)", "NCTID": "NCT04740190", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "E314fs*3", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)", "NCTID": "NCT02264678", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "E314fs*3", "Title": "Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)", "StudyPhase": "PHASE 1/2", "Target": "XPO1, PARP", "Locations": "Singapore (Singapore)", "NCTID": "NCT05035745", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "E314fs*3", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "E314fs*3", "Title": "Trial of Niraparib in Participants With Newly_diagnosed Glioblastoma and Recurrent Glioma", "StudyPhase": "PHASE null", "Target": "PARP", "Locations": "Arizona", "NCTID": "NCT05076513", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "E314fs*3", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "E314fs*3", "Title": "Testing the Addition of an Anti_cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN", "StudyPhase": "PHASE 1/2", "Target": "PD_1, CTLA_4, PI3K", "Locations": "Toronto (Canada), Texas, Virginia", "NCTID": "NCT04317105", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "E314fs*3", "Title": "PARP Inhibition for Gliomas (PI_4G or \u03c04g)", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Oklahoma", "NCTID": "NCT05297864", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "E314fs*3", "Title": "Phase I/II Study of the Anti_Programmed Death Ligand_1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers", "StudyPhase": "PHASE 1/2", "Target": "PARP, VEGFRs, PDGFRA, PDGFRB, KIT, PD_L1", "Locations": "Maryland", "NCTID": "NCT02484404", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "12833145", "FullCitation": "Anastasi S, et al. Oncogene (2003) pmid: 12833145", "Include": "true"}, {"number": "1", "ReferenceId": "17599051", "FullCitation": "Anastasi S, et al. Oncogene (2007) pmid: 17599051", "Include": "true"}, {"number": "2", "ReferenceId": "18046415", "FullCitation": "Zhang X, et al. Nature (2007) pmid: 18046415", "Include": "true"}, {"number": "3", "ReferenceId": "15856022", "FullCitation": "Anastasi S, et al. Oncogene (2005) pmid: 15856022", "Include": "true"}, {"number": "4", "ReferenceId": "12226756", "FullCitation": "Fiorini M, et al. Oncogene (2002) pmid: 12226756", "Include": "true"}, {"number": "5", "ReferenceId": "20421427", "FullCitation": "Frosi Y, et al. J. Cell Biol. (2010) pmid: 20421427", "Include": "true"}, {"number": "6", "ReferenceId": "20351267", "FullCitation": "Ying H, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20351267", "Include": "true"}, {"number": "7", "ReferenceId": "16648858", "FullCitation": "Ferby I, et al. Nat. Med. (2006) pmid: 16648858", "Include": "true"}, {"number": "8", "ReferenceId": "20044804", "FullCitation": "Reschke M, et al. Hepatology (2010) pmid: 20044804", "Include": "true"}, {"number": "9", "ReferenceId": "16819504", "FullCitation": "Zhang YW, et al. Oncogene (2007) pmid: 16819504", "Include": "true"}, {"number": "10", "ReferenceId": "11843178", "FullCitation": "Hackel PO, et al. Biol. Chem. (2001) pmid: 11843178", "Include": "true"}, {"number": "11", "ReferenceId": "11003669", "FullCitation": "Fiorentino L, et al. Mol. Cell. Biol. (2000) pmid: 11003669", "Include": "true"}, {"number": "12", "ReferenceId": "24120142", "FullCitation": "Brennan CW, et al. Cell (2013) pmid: 24120142", "Include": "true"}, {"number": "13", "ReferenceId": "26824661", "FullCitation": "Ceccarelli M, et al. Cell (2016) pmid: 26824661", "Include": "true"}, {"number": "14", "ReferenceId": "28481359", "FullCitation": "Zehir A, et al. Nat. Med. (2017) pmid: 28481359", "Include": "true"}, {"number": "15", "ReferenceId": "24550739", "FullCitation": "Borad MJ, et al. PLoS Genet. (2014) pmid: 24550739", "Include": "true"}, {"number": "16", "ReferenceId": "23868981", "FullCitation": "Walsh AM, et al. J. Cell. Sci. (2013) pmid: 23868981", "Include": "true"}, {"number": "17", "ReferenceId": "18337605", "FullCitation": "Ciardiello F, et al. N. Engl. J. Med. (2008) pmid: 18337605", "Include": "true"}, {"number": "18", "ReferenceId": "17177598", "FullCitation": "Lee JC, et al. PLoS Med. (2006) pmid: 17177598", "Include": "true"}, {"number": "19", "ReferenceId": "22588883", "FullCitation": "Vivanco I, et al. Cancer Discov (2012) pmid: 22588883", "Include": "true"}, {"number": "20", "ReferenceId": "31263031", "FullCitation": "Jonsson P, et al. Clin. Cancer Res. (2019) pmid: 31263031", "Include": "true"}, {"number": "21", "ReferenceId": "28472509", "FullCitation": "Thomas AA, et al. Neuro_oncology (2017) pmid: 28472509", "Include": "true"}, {"number": "22", "ReferenceId": "11504770", "FullCitation": "Smith JS, et al. J. Natl. Cancer Inst. (2001) pmid: 11504770", "Include": "true"}, {"number": "23", "ReferenceId": "14583498", "FullCitation": "Shinojima N, et al. Cancer Res. (2003) pmid: 14583498", "Include": "true"}, {"number": "24", "ReferenceId": "21133628", "FullCitation": "Ambroise MM, et al. Asian Pac. J. Cancer Prev. (2010) pmid: 21133628", "Include": "true"}, {"number": "25", "ReferenceId": "22472960", "FullCitation": "Hobbs J, et al. Am. J. Surg. Pathol. (2012) pmid: 22472960", "Include": "true"}, {"number": "26", "ReferenceId": "22285168", "FullCitation": "Rosell R, et al. Lancet Oncol. (2012) pmid: 22285168", "Include": "true"}, {"number": "27", "ReferenceId": "24263064", "FullCitation": "Douillard JY, et al. Br. J. Cancer (2014) pmid: 24263064", "Include": "true"}, {"number": "28", "ReferenceId": "32673682", "FullCitation": "Hayashi T, et al. Hum Pathol (2020) pmid: 32673682", "Include": "true"}, {"number": "29", "ReferenceId": "29780256", "FullCitation": "Cao L, et al. Onco Targets Ther (2018) pmid: 29780256", "Include": "true"}, {"number": "30", "ReferenceId": "21422421", "FullCitation": "Yang TY, et al. J. Clin. Oncol. (2011) pmid: 21422421", "Include": "true"}, {"number": "31", "ReferenceId": "23816960", "FullCitation": "Sequist LV, et al. J. Clin. Oncol. (2013) pmid: 23816960", "Include": "true"}, {"number": "32", "ReferenceId": "30127622", "FullCitation": "Qin BD, et al. Onco Targets Ther (2018) pmid: 30127622", "Include": "true"}, {"number": "33", "ReferenceId": "27131295", "FullCitation": "Frega S, et al. J Thorac Oncol (2016) pmid: 27131295", "Include": "true"}, {"number": "34", "ReferenceId": "33116645", "FullCitation": "Long X, et al. Onco Targets Ther (2020) pmid: 33116645", "Include": "true"}, {"number": "35", "ReferenceId": "29864379", "FullCitation": "Mok TS, et al. J. Clin. Oncol. (2018) pmid: 29864379", "Include": "true"}, {"number": "36", "ReferenceId": "25923549", "FullCitation": "J\u00e4nne PA, et al. N. Engl. J. Med. (2015) pmid: 25923549", "Include": "true"}, {"number": "37", "ReferenceId": "32749686", "FullCitation": "Hong MH, et al. Cancer (2020) pmid: 32749686", "Include": "true"}, {"number": "38", "ReferenceId": "26462025", "FullCitation": "Kim HS, et al. Oncotarget (2015) pmid: 26462025", "Include": "true"}, {"number": "39", "ReferenceId": "25424851", "FullCitation": "Kim HS, et al. Clin. Cancer Res. (2015) pmid: 25424851", "Include": "true"}, {"number": "40", "ReferenceId": "32303840", "FullCitation": "Mondal G, et al. Acta Neuropathol (2020) pmid: 32303840", "Include": "true"}, {"number": "41", "ReferenceId": "29734047", "FullCitation": "Cavalieri S, et al. Eur. J. Cancer (2018) pmid: 29734047", "Include": "true"}, {"number": "42", "ReferenceId": "32923886", "FullCitation": "Chi AS, et al. JCO Precis Oncol (2020) pmid: 32923886", "Include": "true"}, {"number": "43", "ReferenceId": "31769726", "FullCitation": "Makhlin I, et al. CNS Oncol (2019) pmid: 31769726", "Include": "true"}, {"number": "44", "ReferenceId": "33940677", "FullCitation": "Goyal A, et al. World Neurosurg (2021) pmid: 33940677", "Include": "true"}, {"number": "45", "ReferenceId": "11237521", "FullCitation": "Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521", "Include": "true"}, {"number": "46", "ReferenceId": "12857747", "FullCitation": "Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747", "Include": "true"}, {"number": "47", "ReferenceId": "21828076", "FullCitation": "Rodr\u00edguez_Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076", "Include": "true"}, {"number": "48", "ReferenceId": "23475934", "FullCitation": "He X, et al. Cancer Res. (2013) pmid: 23475934", "Include": "true"}, {"number": "49", "ReferenceId": "10866302", "FullCitation": "Han SY, et al. Cancer Res. (2000) pmid: 10866302", "Include": "true"}, {"number": "50", "ReferenceId": "9811831", "FullCitation": "Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831", "Include": "true"}, {"number": "51", "ReferenceId": "24498881", "FullCitation": "Pradella LM, et al. BMC Cancer (2014) pmid: 24498881", "Include": "true"}, {"number": "52", "ReferenceId": "21536651", "FullCitation": "Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651", "Include": "true"}, {"number": "53", "ReferenceId": "17213812", "FullCitation": "Denning G, et al. Oncogene (2007) pmid: 17213812", "Include": "true"}, {"number": "54", "ReferenceId": "16619501", "FullCitation": "Hlobilkova A, et al. Anticancer Res. () pmid: 16619501", "Include": "true"}, {"number": "55", "ReferenceId": "20718038", "FullCitation": "Redfern RE, et al. Protein Sci. (2010) pmid: 20718038", "Include": "true"}, {"number": "56", "ReferenceId": "22505997", "FullCitation": "Shenoy S, et al. PLoS ONE (2012) pmid: 22505997", "Include": "true"}, {"number": "57", "ReferenceId": "19329485", "FullCitation": "Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485", "Include": "true"}, {"number": "58", "ReferenceId": "16829519", "FullCitation": "Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519", "Include": "true"}, {"number": "59", "ReferenceId": "10555148", "FullCitation": "Lee JO, et al. Cell (1999) pmid: 10555148", "Include": "true"}, {"number": "60", "ReferenceId": "9635567", "FullCitation": "Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567", "Include": "true"}, {"number": "61", "ReferenceId": "9865913", "FullCitation": "Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913", "Include": "true"}, {"number": "62", "ReferenceId": "11051241", "FullCitation": "Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241", "Include": "true"}, {"number": "63", "ReferenceId": "22891331", "FullCitation": "Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331", "Include": "true"}, {"number": "64", "ReferenceId": "23066114", "FullCitation": "Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114", "Include": "true"}, {"number": "65", "ReferenceId": "19457929", "FullCitation": "Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929", "Include": "true"}, {"number": "66", "ReferenceId": "23995781", "FullCitation": "Liu J, et al. Oncogene (2014) pmid: 23995781", "Include": "true"}, {"number": "67", "ReferenceId": "11395408", "FullCitation": "Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408", "Include": "true"}, {"number": "68", "ReferenceId": "10807691", "FullCitation": "De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691", "Include": "true"}, {"number": "69", "ReferenceId": "10051603", "FullCitation": "Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603", "Include": "true"}, {"number": "70", "ReferenceId": "15988030", "FullCitation": "Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030", "Include": "true"}, {"number": "71", "ReferenceId": "15026806", "FullCitation": "Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806", "Include": "true"}, {"number": "72", "ReferenceId": "25875300", "FullCitation": "Gil A, et al. PLoS ONE (2015) pmid: 25875300", "Include": "true"}, {"number": "73", "ReferenceId": "9823298", "FullCitation": "Furnari FB, et al. Cancer Res. (1998) pmid: 9823298", "Include": "true"}, {"number": "74", "ReferenceId": "25527629", "FullCitation": "Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629", "Include": "true"}, {"number": "75", "ReferenceId": "29706633", "FullCitation": "Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633", "Include": "true"}, {"number": "76", "ReferenceId": "20538496", "FullCitation": "Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496", "Include": "true"}, {"number": "77", "ReferenceId": "17942903", "FullCitation": "Andr\u00e9s_Pons A, et al. Cancer Res. (2007) pmid: 17942903", "Include": "true"}, {"number": "78", "ReferenceId": "15805158", "FullCitation": "Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158", "Include": "true"}, {"number": "79", "ReferenceId": "10468583", "FullCitation": "Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583", "Include": "true"}, {"number": "80", "ReferenceId": "12085208", "FullCitation": "Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208", "Include": "true"}, {"number": "81", "ReferenceId": "24292679", "FullCitation": "Nguyen HN, et al. Oncogene (2014) pmid: 24292679", "Include": "true"}, {"number": "82", "ReferenceId": "19114656", "FullCitation": "Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656", "Include": "true"}, {"number": "83", "ReferenceId": "12808147", "FullCitation": "Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147", "Include": "true"}, {"number": "84", "ReferenceId": "18498243", "FullCitation": "Wang X, et al. Biochem. J. (2008) pmid: 18498243", "Include": "true"}, {"number": "85", "ReferenceId": "15951562", "FullCitation": "Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562", "Include": "true"}, {"number": "86", "ReferenceId": "25263454", "FullCitation": "Nguyen HN, et al. Oncogene (2015) pmid: 25263454", "Include": "true"}, {"number": "87", "ReferenceId": "32704382", "FullCitation": "Shan L, et al. Cell Discov (2020) pmid: 32704382", "Include": "true"}, {"number": "88", "ReferenceId": "10096247", "FullCitation": "Zhou XP, et al. Int. J. Cancer (1999) pmid: 10096247", "Include": "true"}, {"number": "89", "ReferenceId": "9331072", "FullCitation": "Rasheed BK, et al. Cancer Res. (1997) pmid: 9331072", "Include": "true"}, {"number": "90", "ReferenceId": "10188904", "FullCitation": "Davies MP, et al. Br. J. Cancer (1999) pmid: 10188904", "Include": "true"}, {"number": "91", "ReferenceId": "9796977", "FullCitation": "Lin H, et al. Clin. Cancer Res. (1998) pmid: 9796977", "Include": "true"}, {"number": "92", "ReferenceId": "10560660", "FullCitation": "Schmidt EE, et al. J. Neuropathol. Exp. Neurol. (1999) pmid: 10560660", "Include": "true"}, {"number": "93", "ReferenceId": "17974913", "FullCitation": "Furnari FB, et al. Genes Dev. (2007) pmid: 17974913", "Include": "true"}, {"number": "94", "ReferenceId": "26061751", "FullCitation": "Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751", "Include": "true"}, {"number": "95", "ReferenceId": "21134002", "FullCitation": "Srividya MR, et al. Neuropathology (2011) pmid: 21134002", "Include": "true"}, {"number": "96", "ReferenceId": "20085938", "FullCitation": "Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938", "Include": "true"}, {"number": "97", "ReferenceId": "27672108", "FullCitation": "Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108", "Include": "true"}, {"number": "98", "ReferenceId": "28220839", "FullCitation": "Milella M, et al. Sci Rep (2017) pmid: 28220839", "Include": "true"}, {"number": "99", "ReferenceId": "23582881", "FullCitation": "Templeton AJ, et al. Eur. Urol. (2013) pmid: 23582881", "Include": "true"}, {"number": "100", "ReferenceId": "34246347", "FullCitation": "Sweeney C, et al. Lancet (2021) pmid: 34246347", "Include": "true"}, {"number": "101", "ReferenceId": "30037818", "FullCitation": "de Bono JS, et al. Clin. Cancer Res. (2019) pmid: 30037818", "Include": "true"}, {"number": "102", "ReferenceId": "27872130", "FullCitation": "Saura C, et al. Cancer Discov (2017) pmid: 27872130", "Include": "true"}, {"number": "103", "ReferenceId": "30327302", "FullCitation": "Voss MH, et al. Clin. Cancer Res. (2018) pmid: 30327302", "Include": "true"}, {"number": "104", "ReferenceId": "27091708", "FullCitation": "Andr\u00e9 F, et al. J. Clin. Oncol. (2016) pmid: 27091708", "Include": "true"}, {"number": "105", "ReferenceId": "31841354", "FullCitation": "Schmid P, et al. J. Clin. Oncol. (2019) pmid: 31841354", "Include": "true"}, {"number": "106", "ReferenceId": "30302599", "FullCitation": "Weldon Gilcrease G, et al. Invest New Drugs (2019) pmid: 30302599", "Include": "true"}, {"number": "107", "ReferenceId": "20049735", "FullCitation": "Mendes_Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735", "Include": "true"}, {"number": "108", "ReferenceId": "23881923", "FullCitation": "Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923", "Include": "true"}, {"number": "109", "ReferenceId": "23565244", "FullCitation": "Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244", "Include": "true"}, {"number": "110", "ReferenceId": "26905328", "FullCitation": "McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328", "Include": "true"}, {"number": "111", "ReferenceId": "21468130", "FullCitation": "Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130", "Include": "true"}, {"number": "112", "ReferenceId": "33242536", "FullCitation": "Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536", "Include": "true"}, {"number": "113", "ReferenceId": "33970096", "FullCitation": "Pan M, et al. Perm J (2021) pmid: 33970096", "Include": "true"}, {"number": "114", "ReferenceId": "23810788", "FullCitation": "Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788", "Include": "true"}, {"number": "115", "ReferenceId": "32988624", "FullCitation": "Romero I, et al. Gynecol Oncol (2020) pmid: 32988624", "Include": "true"}, {"number": "116", "ReferenceId": "18781191", "FullCitation": "Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191", "Include": "true"}, {"number": "117", "ReferenceId": "18794875", "FullCitation": "Orloff MS, et al. Oncogene (2008) pmid: 18794875", "Include": "true"}, {"number": "118", "ReferenceId": "17167516", "FullCitation": "Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516", "Include": "true"}, {"number": "119", "ReferenceId": "22015685", "FullCitation": "Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685", "Include": "true"}, {"number": "120", "ReferenceId": "9282118", "FullCitation": "Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118", "Include": "true"}, {"number": "121", "ReferenceId": "7605428", "FullCitation": "Kim NW, et al. Science (1994) pmid: 7605428", "Include": "true"}, {"number": "122", "ReferenceId": "10647931", "FullCitation": "Hanahan D, et al. Cell (2000) pmid: 10647931", "Include": "true"}, {"number": "123", "ReferenceId": "23348503", "FullCitation": "Horn S, et al. Science (2013) pmid: 23348503", "Include": "true"}, {"number": "124", "ReferenceId": "23348506", "FullCitation": "Huang FW, et al. Science (2013) pmid: 23348506", "Include": "true"}, {"number": "125", "ReferenceId": "23887589", "FullCitation": "Vinagre J, et al. Nat Commun (2013) pmid: 23887589", "Include": "true"}, {"number": "126", "ReferenceId": "23530248", "FullCitation": "Killela PJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23530248", "Include": "true"}, {"number": "127", "ReferenceId": "24722048", "FullCitation": "Killela PJ, et al. Oncotarget (2014) pmid: 24722048", "Include": "true"}, {"number": "128", "ReferenceId": "23955565", "FullCitation": "Nonoguchi N, et al. Acta Neuropathol. (2013) pmid: 23955565", "Include": "true"}, {"number": "129", "ReferenceId": "23603989", "FullCitation": "Liu X, et al. Cell Cycle (2013) pmid: 23603989", "Include": "true"}, {"number": "130", "ReferenceId": "24154961", "FullCitation": "Koelsche C, et al. Acta Neuropathol. (2013) pmid: 24154961", "Include": "true"}, {"number": "131", "ReferenceId": "23764841", "FullCitation": "Arita H, et al. Acta Neuropathol. (2013) pmid: 23764841", "Include": "true"}, {"number": "132", "ReferenceId": "24217890", "FullCitation": "Reitman ZJ, et al. Acta Neuropathol. (2013) pmid: 24217890", "Include": "true"}, {"number": "133", "ReferenceId": "27245281", "FullCitation": "Nat Rev Clin Oncol (2017) pmid: 27245281", "Include": "true"}, {"number": "134", "ReferenceId": "29249395", "FullCitation": "Duperret EK, et al. Mol Ther (2018) pmid: 29249395", "Include": "true"}, {"number": "135", "ReferenceId": "25467017", "FullCitation": "Chiappori AA, et al. Ann Oncol (2015) pmid: 25467017", "Include": "true"}, {"number": "136", "ReferenceId": "33293629", "FullCitation": "Weller M, et al. Nat Rev Clin Oncol (2021) pmid: 33293629", "Include": "true"}, {"number": "137", "ReferenceId": "34185076", "FullCitation": "Louis DN, et al. Neuro Oncol (2021) pmid: 34185076", "Include": "true"}, {"number": "138", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "139", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "140", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "141", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "142", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "143", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "144", "ReferenceId": "11280776", "FullCitation": "Alonso M, et al. Cancer Res. (2001) pmid: 11280776", "Include": "true"}, {"number": "145", "ReferenceId": "24073290", "FullCitation": "Rodr\u00edguez_Hern\u00e1ndez I, et al. PLoS ONE (2013) pmid: 24073290", "Include": "true"}, {"number": "146", "ReferenceId": "18053027", "FullCitation": "Vladimirova V, et al. Neuropathol. Appl. Neurobiol. (2008) pmid: 18053027", "Include": "true"}, {"number": "147", "ReferenceId": "15331927", "FullCitation": "Martinez R, et al. Oncology (2004) pmid: 15331927", "Include": "true"}, {"number": "148", "ReferenceId": "15672285", "FullCitation": "Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285", "Include": "true"}, {"number": "149", "ReferenceId": "17498554", "FullCitation": "Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554", "Include": "true"}, {"number": "150", "ReferenceId": "12908754", "FullCitation": "Szybka M, et al. Clin. Neuropathol. () pmid: 12908754", "Include": "true"}, {"number": "151", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "152", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "153", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "154", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "155", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "156", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "157", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "158", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "159", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "160", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "161", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "162", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "163", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "164", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "165", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "166", "ReferenceId": "32322066", "FullCitation": "Touat M, et al. Nature (2020) pmid: 32322066", "Include": "true"}, {"number": "167", "ReferenceId": "30742119", "FullCitation": "Zhao J, et al. Nat. Med. (2019) pmid: 30742119", "Include": "true"}, {"number": "168", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "169", "ReferenceId": "27001570", "FullCitation": "Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570", "Include": "true"}, {"number": "170", "ReferenceId": "27683556", "FullCitation": "Johanns TM, et al. Cancer Discov (2016) pmid: 27683556", "Include": "true"}, {"number": "171", "ReferenceId": "30073642", "FullCitation": "Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642", "Include": "true"}, {"number": "172", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "173", "ReferenceId": "32386112", "FullCitation": "Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112", "Include": "true"}, {"number": "174", "ReferenceId": "28912153", "FullCitation": "Johnson A, et al. Oncologist (2017) pmid: 28912153", "Include": "true"}, {"number": "175", "ReferenceId": "26699864", "FullCitation": "Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864", "Include": "true"}, {"number": "176", "ReferenceId": "32164609", "FullCitation": "Wang L, et al. BMC Cancer (2020) pmid: 32164609", "Include": "true"}, {"number": "177", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "178", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "179", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "180", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "181", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "182", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "183", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "184", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "185", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "186", "ReferenceId": "18650841", "FullCitation": "Burkhart DL, et al. Nat. Rev. Cancer (2008) pmid: 18650841", "Include": "true"}, {"number": "187", "ReferenceId": "19143056", "FullCitation": "Knudsen ES, et al. Nat. Rev. Cancer (2008) pmid: 19143056", "Include": "true"}, {"number": "188", "ReferenceId": "20594292", "FullCitation": "Berge EO, et al. Mol. Cancer (2010) pmid: 20594292", "Include": "true"}, {"number": "189", "ReferenceId": "16936740", "FullCitation": "Giacinti C, et al. Oncogene (2006) pmid: 16936740", "Include": "true"}, {"number": "190", "ReferenceId": "9342358", "FullCitation": "Otterson GA, et al. Proc. Natl. Acad. Sci. U.S.A. (1997) pmid: 9342358", "Include": "true"}, {"number": "191", "ReferenceId": "10486322", "FullCitation": "Otterson GA, et al. Am. J. Hum. Genet. (1999) pmid: 10486322", "Include": "true"}, {"number": "192", "ReferenceId": "1534305", "FullCitation": "Qin XQ, et al. Genes Dev. (1992) pmid: 1534305", "Include": "true"}, {"number": "193", "ReferenceId": "16360038", "FullCitation": "Rubin SM, et al. Cell (2005) pmid: 16360038", "Include": "true"}, {"number": "194", "ReferenceId": "16449662", "FullCitation": "Sun H, et al. Mol. Cell. Biol. (2006) pmid: 16449662", "Include": "true"}, {"number": "195", "ReferenceId": "21470325", "FullCitation": "Kim YH, et al. Brain Pathol. (2011) pmid: 21470325", "Include": "true"}, {"number": "196", "ReferenceId": "8806696", "FullCitation": "Ichimura K, et al. Oncogene (1996) pmid: 8806696", "Include": "true"}, {"number": "197", "ReferenceId": "7979217", "FullCitation": "Henson JW, et al. Ann. Neurol. (1994) pmid: 7979217", "Include": "true"}, {"number": "198", "ReferenceId": "12556968", "FullCitation": "Gonzalez_Gomez P, et al. Br. J. Cancer (2003) pmid: 12556968", "Include": "true"}, {"number": "199", "ReferenceId": "17016577", "FullCitation": "Ohta T, et al. Oncol. Rep. (2006) pmid: 17016577", "Include": "true"}, {"number": "200", "ReferenceId": "15970925", "FullCitation": "B\u00e4cklund LM, et al. Br. J. Cancer (2005) pmid: 15970925", "Include": "true"}, {"number": "201", "ReferenceId": "22222631", "FullCitation": "Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631", "Include": "true"}, {"number": "202", "ReferenceId": "30373917", "FullCitation": "Gong X, et al. Cancer Discov (2019) pmid: 30373917", "Include": "true"}, {"number": "203", "ReferenceId": "30373918", "FullCitation": "Oser MG, et al. Cancer Discov (2019) pmid: 30373918", "Include": "true"}, {"number": "204", "ReferenceId": "34741392", "FullCitation": "Yang W, et al. Kaohsiung J Med Sci (2022) pmid: 34741392", "Include": "true"}, {"number": "205", "ReferenceId": "30232224", "FullCitation": "Beltran H, et al. Clin. Cancer Res. (2019) pmid: 30232224", "Include": "true"}, {"number": "206", "ReferenceId": "21955141", "FullCitation": "Allaman_Pillet N, et al. Ophthalmic Genet. () pmid: 21955141", "Include": "true"}, {"number": "207", "ReferenceId": "21875955", "FullCitation": "Viatour P, et al. J. Exp. Med. (2011) pmid: 21875955", "Include": "true"}, {"number": "208", "ReferenceId": "24282159", "FullCitation": "Chen Z, et al. Hum. Mutat. (2014) pmid: 24282159", "Include": "true"}, {"number": "209", "ReferenceId": "22553621", "FullCitation": "Yun J, et al. Int J Ophthalmol (2011) pmid: 22553621", "Include": "true"}, {"number": "210", "ReferenceId": "21139478", "FullCitation": "Houston SK, et al. Int Ophthalmol Clin (2011) pmid: 21139478", "Include": "true"}, {"number": "211", "ReferenceId": "19959033", "FullCitation": "Ng AK, et al. Semin Radiat Oncol (2010) pmid: 19959033", "Include": "true"}, {"number": "212", "ReferenceId": "16282176", "FullCitation": "Mellinghoff IK, et al. N. Engl. J. Med. (2005) pmid: 16282176", "Include": "true"}, {"number": "213", "ReferenceId": "19075262", "FullCitation": "Prados MD, et al. J. Clin. Oncol. (2009) pmid: 19075262", "Include": "true"}, {"number": "214", "ReferenceId": "22946346", "FullCitation": "Kesavabhotla K, et al. J. Exp. Ther. Oncol. (2012) pmid: 22946346", "Include": "true"}, {"number": "215", "ReferenceId": "23328813", "FullCitation": "Peereboom DM, et al. Neuro_oncology (2013) pmid: 23328813", "Include": "true"}, {"number": "216", "ReferenceId": "29320312", "FullCitation": "Hainsworth JD, et al. J. Clin. Oncol. (2018) pmid: 29320312", "Include": "true"}, {"number": "217", "ReferenceId": "29998897", "FullCitation": "Nie KK, et al. Chin Med J (Engl) (2018) pmid: 29998897", "Include": "true"}, {"number": "218", "ReferenceId": "20493771", "FullCitation": "Cappuzzo F, et al. Lancet Oncol. (2010) pmid: 20493771", "Include": "true"}, {"number": "219", "ReferenceId": "31194613", "FullCitation": "Zhong WZ, et al. J. Clin. Oncol. (2019) pmid: 31194613", "Include": "true"}, {"number": "220", "ReferenceId": "22056888", "FullCitation": "Petrelli F, et al. Clin Lung Cancer (2012) pmid: 22056888", "Include": "true"}, {"number": "221", "ReferenceId": "35636696", "FullCitation": "Kenmotsu H, et al. J Thorac Oncol (2022) pmid: 35636696", "Include": "true"}, {"number": "222", "ReferenceId": "32139298", "FullCitation": "Oxnard GR, et al. Ann. Oncol. (2020) pmid: 32139298", "Include": "true"}, {"number": "223", "ReferenceId": "31825714", "FullCitation": "Cho JH, et al. J. Clin. Oncol. (2019) pmid: 31825714", "Include": "true"}, {"number": "224", "ReferenceId": "29151359", "FullCitation": "Soria JC, et al. N. Engl. J. Med. (2018) pmid: 29151359", "Include": "true"}, {"number": "225", "ReferenceId": "31751012", "FullCitation": "Ramalingam SS, et al. N. Engl. J. Med. (2019) pmid: 31751012", "Include": "true"}, {"number": "226", "ReferenceId": "34498213", "FullCitation": "Cardona AF, et al. J Neurooncol (2021) pmid: 34498213", "Include": "true"}, {"number": "227", "ReferenceId": "33318755", "FullCitation": "Alanazi A, et al. Lung Cancer Manag (2020) pmid: 33318755", "Include": "true"}, {"number": "228", "ReferenceId": "30255937", "FullCitation": "Wang J, et al. Int. J. Cancer (2019) pmid: 30255937", "Include": "true"}, {"number": "229", "ReferenceId": "17353924", "FullCitation": "Franceschi E, et al. Br. J. Cancer (2007) pmid: 17353924", "Include": "true"}, {"number": "230", "ReferenceId": "23182702", "FullCitation": "Chakravarti A, et al. Int. J. Radiat. Oncol. Biol. Phys. (2013) pmid: 23182702", "Include": "true"}, {"number": "231", "ReferenceId": "21471286", "FullCitation": "Hegi ME, et al. Mol. Cancer Ther. (2011) pmid: 21471286", "Include": "true"}, {"number": "232", "ReferenceId": "22370314", "FullCitation": "Han JY, et al. J. Clin. Oncol. (2012) pmid: 22370314", "Include": "true"}, {"number": "233", "ReferenceId": "20573926", "FullCitation": "Maemondo M, et al. N. Engl. J. Med. (2010) pmid: 20573926", "Include": "true"}, {"number": "234", "ReferenceId": "20022809", "FullCitation": "Mitsudomi T, et al. Lancet Oncol. (2010) pmid: 20022809", "Include": "true"}, {"number": "235", "ReferenceId": "19692680", "FullCitation": "Mok TS, et al. N. Engl. J. Med. (2009) pmid: 19692680", "Include": "true"}, {"number": "236", "ReferenceId": "25329826", "FullCitation": "Qi WX, et al. Curr Med Res Opin (2015) pmid: 25329826", "Include": "true"}, {"number": "237", "ReferenceId": "25546556", "FullCitation": "Zhao H, et al. J Thorac Oncol (2015) pmid: 25546556", "Include": "true"}, {"number": "238", "ReferenceId": "26398831", "FullCitation": "Baik CS, et al. J Thorac Oncol (2015) pmid: 26398831", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_01_24 19:32:09", "OpName": "J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "729x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "4 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "BRAIN", "disease_ontology": "Brain anaplastic astrocytoma", "flowcell_analysis": "2000027089", "gender": "male", "pathology_diagnosis": "Anaplastic Astrocytoma", "percent_tumor_nuclei": "35", "pipeline_version": "v3.19.0", "purity_assessment": "40.0", "specimen": "ORD_1544965_01*US1477649.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1544965_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Brain", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "725.39", "name": "SQ_US1477649.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.25", "cds_effect": "866C>T", "depth": "1048", "equivocal": "false", "functional_effect": "missense", "gene": "EGFR", "percent_reads": "25.0", "position": "chr7:55221822", "protein_effect": "A289V", "status": "known", "strand": "+", "transcript": "NM_005228", "dna_evidence": {"sample": "SQ_US1477649.01_1"}}, {"allele_fraction": "0.4737", "cds_effect": "4689G>C", "depth": "551", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH1", "percent_reads": "47.37", "position": "chr9:139399454", "protein_effect": "E1563D", "status": "unknown", "strand": "_", "transcript": "NM_017617", "dna_evidence": {"sample": "SQ_US1477649.01_1"}}, {"allele_fraction": "0.2582", "cds_effect": "304G>A", "depth": "697", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH3", "percent_reads": "25.82", "position": "chr19:15303224", "protein_effect": "A102T", "status": "unknown", "strand": "_", "transcript": "NM_000435", "dna_evidence": {"sample": "SQ_US1477649.01_1"}}, {"allele_fraction": "0.6271", "cds_effect": "3796G>A", "depth": "606", "equivocal": "false", "functional_effect": "missense", "gene": "DOT1L", "percent_reads": "62.71", "position": "chr19:2226316", "protein_effect": "A1266T", "status": "unknown", "strand": "+", "transcript": "NM_032482", "dna_evidence": {"sample": "SQ_US1477649.01_1"}}, {"allele_fraction": "0.3688", "cds_effect": "_124C>T", "depth": "160", "equivocal": "false", "functional_effect": "promoter", "gene": "TERT", "percent_reads": "36.88", "position": "chr5:1295228", "protein_effect": "promoter _124C>T", "status": "known", "strand": "_", "transcript": "NM_198253", "dna_evidence": {"sample": "SQ_US1477649.01_1"}}, {"allele_fraction": "0.4363", "cds_effect": "1024A>G", "depth": "644", "equivocal": "false", "functional_effect": "missense", "gene": "INPP4B", "percent_reads": "43.63", "position": "chr4:143129626", "protein_effect": "I342V", "status": "unknown", "strand": "_", "transcript": "NM_003866", "dna_evidence": {"sample": "SQ_US1477649.01_1"}}, {"allele_fraction": "0.4825", "cds_effect": "11342G>A", "depth": "771", "equivocal": "false", "functional_effect": "missense", "gene": "MLL2", "percent_reads": "48.25", "position": "chr12:49427146", "protein_effect": "S3781N", "status": "unknown", "strand": "_", "transcript": "NM_003482", "dna_evidence": {"sample": "SQ_US1477649.01_1"}}, {"allele_fraction": "0.4568", "cds_effect": "1972C>T", "depth": "740", "equivocal": "false", "functional_effect": "missense", "gene": "TET2", "percent_reads": "45.68", "position": "chr4:106157071", "protein_effect": "H658Y", "status": "unknown", "strand": "+", "transcript": "NM_001127208", "dna_evidence": {"sample": "SQ_US1477649.01_1"}}, {"allele_fraction": "0.5164", "cds_effect": "682C>T", "depth": "548", "equivocal": "false", "functional_effect": "missense", "gene": "PDCD1LG2", "percent_reads": "51.64", "position": "chr9:5557668", "protein_effect": "P228S", "status": "unknown", "strand": "+", "transcript": "NM_025239", "dna_evidence": {"sample": "SQ_US1477649.01_1"}}, {"allele_fraction": "0.2326", "cds_effect": "3118T>C", "depth": "1367", "equivocal": "false", "functional_effect": "missense", "gene": "MET", "percent_reads": "23.26", "position": "chr7:116415024", "protein_effect": "S1040P", "status": "unknown", "strand": "+", "transcript": "NM_000245", "dna_evidence": {"sample": "SQ_US1477649.01_1"}}, {"allele_fraction": "0.4179", "cds_effect": "942delA", "depth": "347", "equivocal": "false", "functional_effect": "frameshift", "gene": "PTEN", "percent_reads": "41.79", "position": "chr10:89720790", "protein_effect": "E314fs*3", "status": "known", "strand": "+", "transcript": "NM_000314", "dna_evidence": {"sample": "SQ_US1477649.01_1"}}, {"allele_fraction": "0.4781", "cds_effect": "531_545delAGCAGCCGCGGCGGC", "depth": "251", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "GATA6", "percent_reads": "47.81", "position": "chr18:19751635", "protein_effect": "A179_A183del", "status": "unknown", "strand": "+", "transcript": "NM_005257", "dna_evidence": {"sample": "SQ_US1477649.01_1"}}, {"allele_fraction": "0.4776", "cds_effect": "487G>T", "depth": "647", "equivocal": "false", "functional_effect": "missense", "gene": "ALK", "percent_reads": "47.76", "position": "chr2:30143039", "protein_effect": "V163L", "status": "unknown", "strand": "_", "transcript": "NM_004304", "dna_evidence": {"sample": "SQ_US1477649.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "0", "equivocal": "false", "gene": "RB1", "number_of_exons": "10 of 27", "position": "chr13:49027123_49054234", "ratio": "0.35", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1477649.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "ERRFI1", "number_of_exons": "3 of 3", "position": "chr1:8073269_8075681", "ratio": "0.31", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1477649.01_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "3.62", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}